Novogene Co. Ltd.

Company Overview

Novogene, founded in 2011, provides genomics services, including NGS and bioinformatics. The company operates a large sequencing facility in China. The company also has laboratories, subsidiaries or joint ventures in Hong Kong; San Diego; Singapore; the University of California, Davis; and the U.K.

Novogene has a CAP-accredited medical laboratory in Tianjin, China. In this laboratory, the company tests liquid biopsy samples on its digital PCR platform.

In August 2018, Tianjin Novogene Bioinformatics Technology, a subsidiary of Novogene, received approval from the China FDA for its NovoFocus NSCLC CDx assay. This diagnostic test runs on NGS and analyzes tumor samples for genetic mutations targeted by several CDFA-approved therapies for non-small cell lung cancer, including Iressa, Tagrisso and Xalkori. This assay can be used to identify patients who may respond to these therapies.

In July 2019, Novogene formed a partnership with Mission Bio in which Novogene agreed to distribute Mission Bio’s Tapestri platform in China. The Tapestri platform provides droplet-based single-cell DNA profiling for cancer cells and mutations; it can detect rare cancer subclones and co-occurring mutations.

In October 2019, Novogene partnered with Chipscreen Bioscience to develop a companion diagnostic for a cancer drug under development. The drug candidate, chiauranib, is a small molecule inhibitor of key serine-threonine kinases involved in tumor angiogenesis, cell mitosis and microenvironmental inflammation. Novogene agreed to provide molecular testing services to Chipscreen as part of the clinical testing of the drug candidate.

In 2020, Novogene launched FALCON, the first fully automated, intelligent delivery system in the NGS industry. This platform provides highly efficient, reliable and flexible sequencing services. In May 2022, Novogene Europe unveiled Falcon II, an intelligent next-generation sequencing delivery platform, catering specifically to its European customer base.

Financial Highlights (FY 2023)

Company's Business Segments

• Genomics : Whole genome sequencing, Target capture sequencing, De novo sequencing, Metagenome sequencing
• Transcriptomics : Eukaryote, Prokaryote
• Single Cell Omics : Singel cell gene expression, Single cell long read transcriptome
• Epigenomics : Whole genome bisulfite sequencing, Reduced representation bisulfite sequencing, RIP-seq